Parkway Life REIT - DBS Research 2024-11-25: Prescription For Growth

Parkway Life REIT - Prescription For Growth

Published:
Parkway Life REIT (SGX:C2PU) | SGinvestors.io
  • Parkway Life REIT (SGX:C2PU) is one of the top-performing S-REITs in Singapore with a share price return of >4x since its listing 12-13 years ago, with steady return in DPUs over the years.
  • - Read this at SGinvestors.io -

Maiden entry into third key market.

  • Parkway Life REIT announced its first acquisition in its third key market, Europe and UK, with the purchase of 11 nursing homes in France for S$159.9mil, slightly less than the property valuation of S$165.8mil. This was fully funded through an equity fund raising (EFR) via a private placement.
  • - Read this at SGinvestors.io -
  • The acquisition is expected to be completed by 4Q24 and is projected to generate a distribution per unit (DPU) accretion of ~1.4% and net asset value (NAV) accretion of ~4.3%.

Who is DomusVi, the vendor and master-lessee?

  • Read more at SGinvestors.io.




Above is the excerpt from report by DBS Group Research.
Clients of DBS may access the full report in PDF @ https://www.dbs.com/insightsdirect/.




Tabitha FOO DBS Group Research | Derek TAN DBS Group Research | https://www.dbs.com/insightsdirect/ 2024-11-25



Previous report by DBS:
2024-07-29 Parkway Life REIT - The One And Only.

Price targets by 2 other brokers at Parkway Life REIT Target Prices.

Listing of research reports at Parkway Life REIT Analyst Reports.

Relevant links:
Parkway Life REIT Share Price History,
Parkway Life REIT Announcements,
Parkway Life REIT Dividends & Corporate Actions,
Parkway Life REIT News Articles





Advertisement

You May Also Like




SGX Stock / REIT Search

Advertisement

Most Read

Trust Bank God Of Fortune Referral Code PGKPSWAE Trust Bank Referral Code 🎁

Advertisement